ORIGINAL RESEARCH article

Front. Nutr., 24 July 2025

Sec. Nutritional Epidemiology

Volume 12 - 2025 | https://doi.org/10.3389/fnut.2025.1589177

A cross-sectional study of dietary and urinary soy isoflavones about coal-burning fluorosis in Guizhou, China

  • HH

    Hua Han 1†

  • YL

    Yameng Li 2†

  • PL

    Peimin Li 2

  • LL

    Lu Liu 2

  • XZ

    Xingting Zheng 2

  • YZ

    Yuanmei Zhang 3

  • ML

    Min Liu 2

  • XZ

    Xiaogang Zhang 2

  • LT

    Ling Tang 2

  • MG

    Manman Gao 2

  • NT

    Na Tao 4*

  • JL

    Jun Liu 2,5*

  • 1. Department of Clinical Nutrition, The First People’s Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, China

  • 2. Department of Preventive Medicine, School of Public Health, Zunyi Medical University, Zunyi, China

  • 3. Department of Chronic Disease, Center of Disease Control and Prevention of Honghuagang District, Zunyi, China

  • 4. Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, China

  • 5. Key Laboratory of Maternal & Child Health and Exposure Science of Guizhou Higher Education Institutes, Zunyi, China

Article metrics

View details

1,3k

Views

402

Downloads

Abstract

Objective:

Previous research showed soy isoflavones have antioxidant properties beneficial to bone health, but no epidemiological studies reported effects of soy isoflavones on fluorosis. Therefore, the aim of this study was to investigate the relationship between soy isoflavones in diet/urine and coal-burning fluorosis.

Methods:

A comprehensive cross-sectional study with 896 participants in Zhijin County, Guizhou, China, assessed dietary intake through face-to-face interviews using a 75-item food frequency questionnaire. Urine samples were analyzed for soy isoflavone concentrations by HPLC. Unconditional logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations.

Results:

We observed a significant inverse association between dietary soy isoflavones and fluorosis. The adjusted OR (95% CI) in the highest quartile of intake compared with the lowest was 0.61 (0.38–0.97) (p-trend = 0.032) for total soy isoflavones intake, 0.59 (0.37–0.95) (p-trend = 0.032) for daidzein intake. Results of soy isoflavones in urine were consistent with the dietary results.

Conclusion:

Soy isoflavones are associated with the occurrence of coal-burning fluorosis.

1 Introduction

Endemic fluorosis is a condition caused by exposure to high concentrations of fluoride in the environment, primarily manifested as dental fluorosis and skeletal fluorosis. Furthermore, in recent years, theories regarding the pathogenesis of systemic damage induced by endemic fluorosis have emerged (1). This condition has a prevalent range that spans across 13 provinces, with a concentration in areas such as Yunnan, Guizhou, and Sichuan, affecting over 34.3 million people and posing as a worldwide public health issue (2, 3). Although the cases of fluorosis from coal-burning have been reduced through the using of improved stoves and awareness education, the prevalence of fluorosis is still high (4–7). Therefore, further prevention and control of fluorosis is needed.

Soy isoflavones are derived from soy foods, a secondary metabolite in the process of soybean growth, which has antioxidant biological activity and can alleviate cellular oxidative stress (8). Studies have shown that soy isoflavones have a protective effect against oxidative stress-related diseases due to their antioxidant activity, in addition to being closely associated with bone health (9, 10). A large number of observational studies have shown that the higher the intake of soy isoflavones, the higher the bone mineral density (BMD) or the lower the bone resorption markers (11). The latest meta-analyses showed that soy isoflavones exert beneficial effects on bone formation markers that can prevent osteoporosis-related bone loss in any weight status or treatment duration (12–14). Isoflavones may benefit bone because they have positive effects on the osteoblast cell (favoring proliferation, differentiation and mineralization) and hinder osteoclast and adipocyte generation (15, 16). Fluorosis is a disease affecting mainly skeletal system and oxidative stress has been considered as an important pathogenesis of endemic fluorosis (17). Based on the positive effects of soy isoflavones on bone health and antioxidant activity, it is suggested that soy isoflavones may have a certain beneficial effect on fluorosis. Furthermore, animal experiments have found that soy isoflavones can inhibit the lipid peroxidation of liver tissue, enhance the antioxidant capacity, and have protective effects on oxidative damage in fluorosis rats (18), but no epidemiological study has confirmed it.

Therefore, we conducted a cross-sectional study to investigate the associations of external (dietary intake) and internal (urine) exposure levels with fluorosis in coal-burning fluorosis areas of Guizhou, China.

2 Materials and methods

2.1 Study subjects

A population-based cross-sectional study was conducted in a coal-burning area of Zhijin County, Guizhou Province, China. We used a two-stage, clustered random sampling method to ensure the representativeness of the target population. The three towns of Chadian, Chengguan, and Puweng were randomly selected from 10 towns in Zhijin County. Then, we randomly further selected four villages from each selected town. The 12 villages selected for the study were Dazai, Ganhe, Gaofeng, Guihua, Guohua, Hehua, Hualuo, Jiangyan, Moda, Shangzai, Yutang, and Xianfeng. Participants who have lived in Zhijin County for at least 10 years and aged 18–75 years were recruited. Participants were excluded if they had a prior history of cancer, coronary heart disease, stroke, gout, or kidney disease. They were also excluded if their dietary habits had manifestly changed during the previous 5 years, or if they had chronic diseases that might affect their dietary habits, such as gastritis, diabetes, and hypertension. In addition, the participants with incomplete questionnaire information were also excluded. Finally, a total of 896 participants were successfully interviewed out of 1,101 recruited. The urine samples of 720 subjects were obtained from the 896 participants interviewed. It was reported the prevalence of coal-burning fluorosis in Guizhou was 35% (19), allowable error d = 0.15p, and significance level α = 0.05; . The sample size was estimated to be 318 cases based on the sample size estimation formula for cross-sectional studies.

All of the coal-burning fluorosis cases were diagnosed by the Zhijin County Disease Control and Prevention Center according to the Chinese Diagnostic Criteria of Dental Fluorosis (WS/T208-2011, China) and the Chinese Diagnostic Criteria of Endemic Skeletal Fluorosis (WS/T 192-2008, China) (20). Specifically, dental fluorosis was confirmed in individuals with a documented history of excessive fluoride exposure during tooth development, presenting with at least one enamel defect: white non-removable opacities, intrinsic brown/black-brown discoloration, or pitted/map-like hypoplasia. Similarly, skeletal fluorosis was diagnosed in individuals with a documented history of residence in an endemic fluorosis area, presenting with persistent resting pain in ≥3 bony/joint sites (unaffected by weather), joint limitation/neurological deficits (limb deformities, paralysis). Dental fluorosis and skeletal fluorosis were identified by a professional doctor in Zhijin Center for Disease Control and Prevention. Concurrently, non-fluorosis was defined as the absence of pathological changes in individuals, such as dental fluorosis or skeletal fluorosis, despite long-term living in fluorosis area.

This study complied with the Declaration of Helsinki guidelines and was approved by the Zunyi Medical University Medical Ethics Committee (No. 2014-1-003), with all participants providing written informed consent. Using cluster sampling of villages in coal-burning fluorosis-endemic areas, we ensured comprehensive representation of the target population. This approach, combined with a broad age range, redundant sample size, and standardized diagnostics, effectively mitigated selection bias.

2.2 Data collection pertaining to diet and lifestyle

Interviews were conducted by trained interviewers who administered a structured questionnaire in a personal interview. The content of the questionnaire included: (1) socio-demographic characteristics (age, gender, ethnicity, marital status, and education level); (2) lifestyle habits (use of improved stoves, domestic fuel type, use of coal to roast grains and chilies, and washing dry grains and chilies before use); (3) dietary habits in the year before the interview; (4) relevant disease history (hypertension, diabetes, gout, hepatocirrhosis, heart-related diseases). Dietary intake of nutrients intake was collected through a valid and reliable Food-Frequency Questionnaire (FFQ) (21) and assessed never, daily, weekly, monthly, or yearly frequency intake of each food item over the last year. The 75-items FFQ involved seven categories including fruits, animal food, cereals, beans and their products, vegetables, algae and nuts, drinks and soup. The FFQ covered virtually all soy foods that are habitual consumed in the study population, including firm tofu, soft tofu, bean curd skin, soy drink, tofu pudding and fresh and dried soybeans. Energy, soy isoflavones, genistein, daidzein and glycitein and other nutrient intakes were calculated using the Chinese Food Composition Database (22).

2.3 Detection of urinary levels of soy isoflavones

Level of glycitein, genistein, daidzein, dihydrodaidzein, equol, and O-desmethylangolensin in the urine were detected using a high-performance liquid chromatography (HPLC) methods. Briefly, Urine samples were extracted by ethyl acetate after deconjugation by β-glucuronidase/sodium acetate. After nitrogen drying, the extract was reconstituted in mobile phase solution for analysis. The HPLC system consisted of a C18 stationary phase extraction (5 μm, 4.60 mm × 250 mm) column, and separation of soy isoflavones was achieved by gradient elution with the mobile phase of methanol-ethyl acetate at a flow rate of 1.0 mL/min. Soy isoflavones were detected from the UV absorbance at 254 nm. The standards of glycitein, genistein, daidzein, dihydrodaidzein, equol, O-desmethylangolensin and β-glucuronidase were purchased from Sigma Chemical Company (St. Louis, MO, United States).

2.4 Statistical analysis

The data were coded and doubly entered by two data clerks into Epi-Data version 3.1 to avoid clerical errors using side-by-side comparison, and the data were then exported to SPSS for windows version 18 statistical software.

Continuous variables were expressed as mean (M) and SD (s) or median (P25, P75), while categorical variables were expressed as numbers and percentages. Dietary intake of soy isoflavones showed skewed distribution, which was classified into quartiles, and the lowest quartile was used as the reference category. Logistic regression model was used to estimate the relationship between dietary intake of soy isoflavones and coal-burning fluorosis, and the odds ratio (OR) and 95% confidence interval (95% CI) were calculated. The multivariate models were used to adjust the potential confounding factors, such as age, gender, ethnicity, marital status, education level, smoking, alcohol drinking, tea drinking, improved stove use, fuel type and using coal to roast grains and chilies, washing dry grains and chilies before use (Model 1). Subsequent models were adjusted for dietary factors, such as roasted chili consumption, dietary calcium intake, total energy intake, and roasted corn intake (Model 2). Stratified analysis was performed by sex (male/female) to explore whether the association between soy isoflavones and fluorosis was modified. Subgroup analyses for dental fluorosis or skeletal fluorosis were performed for the relationships between soy isoflavones and fluorosis. We also performed sensitivity analysis to assess whether the results of primary analysis were driven by type of fluorosis. All p-values were two tailed, and the level of significance was set at ≤ 0.05.

3 Results

3.1 General characteristics of subjects

Of the 896 participants (414 men and 482 women), 655 were diagnosed with endemic fluorosis and 241 without fluorosis. Table 1 shows the baseline demographic characteristics of the study subjects and selected risk factors for endemic fluorosis. The mean (±) age of fluorosis group was 50.32 years old (±12.41 years old), and that of non-fluorosis group was 47.10 years old (±14.52 years old). Compared with non-fluorosis subjects, fluorosis patients tended to have lower levels of education and annual household income. Moreover, fluorosis patients were less likely to use improved cook stoves, were more likely to use coal to roast grains and chilis, and use mixed coal fuel types. Compared with non-fluorosis subjects, the intake of soy isoflavone in fluorosis patients was lower, and the level of urinary fluoride was higher.

Table 1

CharacteristicsNon-fluorosis (n = 241)Fluorosis (n = 655)T/χ2/Zpa
Age, years (mean ± s)47.10 ± 14.5250.32 ± 12.413.2830.001
Gender, n (%)2.4490.118
 Female140 (58.09)342 (52.21)
 Male101 (41.91)313 (47.79)
Marital status, n (%)4.8810.087
 Married or cohabitation199 (82.60)554 (84.60)
 Divorce or separation23 (9.50)73 (11.10)
 Unmarried19 (7.90)28 (4.30)
Educational years, n (%)60.368<0.001
 ≤3 years84 (34.90)339 (51.80)
 4–6 years74 (30.70)226 (34.50)
 7–11 years55 (22.80)76 (11.60)
 ≥12 years28 (11.60)14 (2.10)
Income (yuan/per capita/month), n (%)10.8040.013
 ≤5009 (3.70)62 (9.50)
 501–200096 (39.80)265 (40.50)
 2001–4,00064 (26.60)178 (27.20)
 >4,00072 (29.90)150 (22.90)
Smokerb, n (%)85 (35.30)279 (42.60)3.9200.048
Alcohol drinkerc, n (%)73 (30.30)204 (31.20)0.0670.796
Tea drinkerd, n (%)90 (37.30)250 (38.30)0.0660.797
Using an improved stovee, n (%)209 (86.70)465 (71.30)22.554<0.001
Fuel type, n (%)18.301<0.001
 Raw coal36 (56.40)394 (60.40)
 Mixed coal41 (17.00)152 (23.30)
 Firewood17 (7.10)15 (2.30)
 Others47 (19.50)91 (14.0)
Using coal to roast grains and chilisf, n (%)114 (47.30)390 (59.80)11.2060.001
Washing dry grains and chilis before use, n (%)227 (96.20)608 (93.80)2.9050.234
Total energy intake (kcal/day)2538.60 (2008.76, 3210.36)2615.86 (1992.06, 3420.85)0.7370.461
Calcium intake (mg/day)481.91 (335.71, 710.39)449.13 (314.42, 655.27)1.7900.074
Total protein intake (mg/day)72.17 (55.09, 107.84)75.47 (54.33, 100.52)0.4060.684
Total fat intake (mg/day)97.65 (71.94, 147.03)101.41 (73.01, 150.86)0.5670.571
Corn intake (g/day)13.69 (4.72, 28.49)13.69 (4.11, 32.87)0.2860.775
Dry chilis intake (g/day)5.78 (2.41, 12.54)5.78 (2.41, 14.46)0.5370.591
Urinary fluoride (mg/L)1.17 (0.81, 1.65)1.41 (1.03, 2.08)4.703<0.001
Soy isoflavones (mg/day)35.39 (16.26, 72.47)27.00 (13.82, 55.21)2.5750.010

Socio-demographic characteristics and selected risk factors of the participants in coal-burning fluorosis area in Guizhou.

a

Between fluorosis and non-fluorosis differences on categorical variables were analyzed with chi-square tests, and on continuous variables were with two independent sample t-tests, incasing of skewed distributions, non-parametric t-test were used. s, SD; n (%), number of cases (proportion).

b

Smokers were defined as smoking at least five packs of cigarettes per year.

c

Alcohol drinkers were defined as having beer, white wine, or red wine at least once weekly over the past year.

d

Tea drinkers were identified as having tea at the least two times per week.

e

Improve open oven to reduce fluoride pollution indoors by excluding fluoride out of room.

f

Burning fluoride-rich coal for roasted grain and chili.

3.2 Comparison of dietary and urinary isoflavones in participants with fluorosis and non-fluorosis

Compared with fluorosis patients, the dietary intake of soy isoflavones was higher in non-fluorosis subjects, and the intake of genistein was the largest in the subclass of soy isoflavones. In addition, compared with fluorosis patients, the contents of soy isoflavone and daidzein metabolites in urine of non-fluorinated subjects were higher, and equol content was the highest in urine (Table 2).

Table 2

Soy isoflavonesNon-fluorosis group median (25th, 75th)Fluorosis group median (25th, 75th)Zpb
Dietary intake (mg/day)N = 241N = 655
 Glycitein1.75 (0.87, 3.84)1.35 (0.68, 2.87)2.7710.006
 Genistein19.41 (8.84, 39.59)14.52 (7.54, 30.69)2.5800.010
 Daidzein14.46 (6.53, 29.03)11.26 (5.57, 22.18)2.5060.012
 Total isoflavones35.37 (16.10, 72.22)27.38 (13.74, 55.12)2.5710.010
Urinary level (ng/mL)N = 192N = 528
 Glycitein22.78 (14.76, 32.13)17.94 (12.84, 26.41)4.194<0.001
 Genistein22.75 (12.21, 32.33)19.92 (10.99, 31.69)1.5740.116
 Daidzein26.28 (15.82, 44.06)18.32 (12.44, 33.09)4.956<0.001
 Dihydrodaidzein17.36 (7.01, 39.14)9.78 (4.31, 21.36)5.167<0.001
 Equol28.57 (16.69, 61.00)21.78 (12.03, 39.12)3.910<0.001
 O-Desmethylangolensin1.36 (0.79, 2.79)1.31 (0.67, 2.30)1.2300.219

Comparison of dietary intake and urinary levels of soy isoflavone between fluorosis and non-fluorosisa.

a

Soy isoflavones, genistein, daidzein and glycitein and other nutrient intakes were calculated using the Chinese Food Composition Database. Level of glycitein, genistein, daidzein, dihydrodaidzein, equol, and O-desmethylangolensin in the urine were detected using a high-performance liquid chromatography (HPLC) methods. P25 and P75 represent the 25th and 75th percentile.

b

Wilcoxon rank sum test was used to compare the median consumption levels between fluorosis and non-fluorosis.

3.3 Associations between dietary soy isoflavones and coal-burning fluorosis

Figure 1A presents the ORs and 95% CIs for fluorosis according to quartiles of dietary soy isoflavone intakes. The quartiles of dietary intake of soy isoflavones from low to high were 6.64 mg/day, 20.72 mg/day, 41.84 mg/day, 99.29 mg/day. With the increase of intake, the proportion of non-fluorosis poisoning increased. Univariate analysis showed that the OR value decreased gradually with the increase of nutrient intake, and the difference between the highest quartile and the lowest quartile of nutrient intake was statistically significant (p = 0.008). After further adjustment for dietary factors such as total energy, calcium intake, grains intake, and dry chilis intake, the negative associations between soy isoflavone intake and the risk of developing coal-burning fluorosis were not changed. The ORs for fluorosis occurrence in the highest quartile compared with the lowest quartile of intake 0.59 (95% CI: 0.37–0.95) for daidzein, 0.61 (95% CI: 0.38–0.97) for total soy isoflavones. Figure 2A indicates the higher dietary intake of daidzein and total isoflavones, the lower the occurrence of fluorosis (both p-trend = 0.032).

Figure 1

Figure 2

3.4 Associations between urinary soy isoflavones and coal-burning fluorosis

For the six soy isoflavone subgroups, compared to the lowest quartile of urinary isoflavone, the ORs for fluorosis occurrence in the highest quartile were 0.27 (95% CI: 0.16–0.0.46) for dihydrodaidzein, 0.33 (95% CI: 0.19–0.56) for daidzein, 0.43 (95% CI: 0.25–0.72) for glycitein and 0.42 (95% CI: 0.25–0.69) for equol (Figure 1B). Figure 2B shows the higher levels of dihydrodaidzein, daidzein, glycitein and equol in the urine, the lower the occurrence of fluorosis after adjusting for various dietary and non-dietary factors (p-trend <0.001–0.034). In contrast, no statistical association was observed between O-desmethylangolensin and fluorosis (p-trend = 0.666).

3.5 Sex-stratified analysis of the relationship between soy isoflavone and coal-burning fluorosis

As shown in Table 3 subgroup analysis showed there were negative associations of total soy isoflavones, glycitein, genistein and daidzein with fluorosis in women (p = 0.013–0.030), but not in men. We observed interactions between dietary soy isoflavone and gender on fluorosis, such as daidzein (p-interaction = 0.009), genistein (p-interaction = 0.012), glycitein (p-interaction = 0.011), total isoflavones (p-interaction = 0.012). Furthermore, there were interactions between urinary O-desmethylangolensin and fluorosis (p-interaction = 0.018) (Table 4 and Supplementary Figure 1). These results indicated effects of different types of soy isoflavones on fluorosis may be vary between men and women.

Table 3

Soy isoflavonesQuartilesp-trendp-interaction
Q1Q2Q3Q4
Total isoflavones0.012
Non-fluorosis/fluorosis52/17253/17160/16476/148
 Female10.95 (0.50, 1.78)0.75 (0.40, 1.41)0.42 (0.22, 0.80)a0.017
 Male10.88 (0.42, 1.84)0.94 (0.45, 1.99)0.84 (0.41, 1.70)0.975
Glycitein0.011
Non-fluorosis/fluorosis49/17557/16763/16172/152
 Female10.72 (0.38, 1.38)0.82 (0.43, 1.55)0.39 (0.20, 0.74)a0.020
 Male10.74 (0.35, 1.53)0.63 (0.30, 1.31)0.92 (0.44, 1.91)0.987
Genistein0.012
Non-fluorosis/fluorosis52/17253/17161/16175/149
 Female10.93 (0.49, 1.74)0.74 (0.40, 1.39)0.45 (0.24, 0.86)a0.030
 Male10.89 (0.42, 1.87)0.88 (0.41, 1.85)0.89 (0.44, 1.82)0.934
Daidzein0.009
Non-fluorosis/fluorosis50/17456/16860/16475/149
 Female10.89 (0.47, 1.69)0.70 (0.37, 1.31)0.41 (0.21, 0.78)a0.013
 Male10.74 (0.35, 1.54)0.86 (0.40, 1.86)0.83 (0.40, 1.69)0.916

Sex-stratified analysis of the relationship between dietary intake of soy isoflavone and fluorosis OR (95% CI).

OR, odds ratio; CI, confidence interval; Q, quartile. The multivariate logistic regression model was used to estimate the relationship between intake of soy isoflavones and fluorosis. Covariates adjusted for age, gender, ethnicity, marital status, education level, smoking, alcohol drinking, tea drinking, improved stove use, fuel type and using coal to roast grains and chilies, washing dry grains and chilis before use, total energy intake, calcium intake.

a

p < 0.05.

Table 4

Soy isoflavonesQuartilesp-trendp-interaction
Q1Q2Q3Q4
Dihydrodaidzein0.109
Non-fluorosis/fluorosis29/15142/13847/13374/106
 Female10.87 (0.40, 1.87)0.74 (0.34, 1.59)0.28 (0.13, 0.58)a0.001
 Male10.40 (0.16, 0.95)a0.37 (0.16, 0.88)a0.24 (0.10, 0.55)a0.001
Daidzein0.100
Non-fluorosis/fluorosis29/15038/14259/12166/114
 Female10.62 (0.27, 1.39)0.45 (0.20, 1.00)0.28 (0.12, 0.61)a0.003
 Male10.76 (0.32, 1.75)0.32 (0.14, 0.71)a0.38 (0.17, 0.84)a0.004
Glycitein0.105
Non-fluorosis/fluorosis35/ 14436/14457/12364/116
 Female10.79 (0.37, 1.70)0.50 (0.24, 1.06)0.44 (0.20, 0.92)a0.032
 Male11.40 (0.58, 3.39)0.58 (0.27, 1.26)0.47 (0.22, 0.99)a0.014
Equol0.308
Non-fluorosis/fluorosis33/14648/13247/13364/116
 Female10.87 (0.42, 1.82)0.85 (0.40, 1.77)0.55 (0.27, 1.11)0.191
 Male10.51 (0.21, 1.21)0.44 (0.18, 1.03)0.26 (0.11, 0.61)a0.002
Genistein0.055
Non-fluorosis/fluorosis40/ 13945/13554/12653/127
 Female10.90 (0.43, 1.92)0.50 (0.25, 1.02)0.59 (0.28, 1.20)0.122
 Male10.94 (0.44, 2.00)0.90 (0.41, 1.94)0.69 (0.32, 1.48)0.375
O-Desmethylangolensin0.018
Non-fluorosis/fluorosis37/14257/12345/13553/127
 Female10.58 (0.28, 1.20)1.25 (0.60, 2.61)0.38 (0.18, 0.79)a0.154
 Male10.51 (0.23, 1.12)0.56 (0.25, 1.28)1.01 (0.44, 2.28)0.771

Sex-stratified analysis of the relationship between urinary levels of soy isoflavones and fluorosis OR (95% CI).

OR, odds ratio; CI, confidence interval; Q, quartile. The multivariate logistic regression model was used to estimate the relationship between urinary levels of soy isoflavones and fluorosis. Covariates adjusted for age, gender, ethnicity, marital status, education level, smoking, alcohol drinking, tea drinking, improved stove use, fuel type and using coal to roast grains and chilies, washing dry grains and chilis before use, total energy intake, calcium intake.

a

p < 0.05.

3.6 Multivariate analysis of soy isoflavone and dental fluorosis and skeletal fluorosis

Fluorosis was divided into dental fluorosis and skeletal fluorosis, thus sensitivity analysis was conducted to assess whether the results of primary analysis were driven by type of fluorosis. Results showed associations of dietary intake and urinary levels of soy isoflavone with dental fluorosis and skeletal fluorosis were in line with fluorosis (Tables 5, 6).

Table 5

Soy isoflavonesQ1Q2Q3Q4p
Dietary intake (mg/day)
Non-DF/DF56/16872/15280/14489/135
Glycitein10.64 (0.41, 1.00)0.62 (0.39, 0.96)a0.52 (0.33, 0.82)a0.007
Non-DF/DF59/16568/15677/14793/131
Genistein10.79 (0.51, 1.23)0.68 (0.43, 1.06)0.55 (0.35, 0.85)a0.007
Non-DF/DF58/16670/15476/14893/131
Daidzein10.74 (0.48, 1.16)0.68 (0.43, 1.06)0.51 (0.33, 0.80)a0.004
Non-DF/DF59/16568/15676/14894/130
Total soy isoflavones10.79 (0.50, 1.23)0.70 (0.45, 1.10)0.51 (0.33, 0.80)a0.003
Urinary isoflavones (ng/mL)
Non-DF/DF46/13447/13369/11176/104
Glycitein10.97 (0.58, 1.62)0.56 (0.34, 0.92)a0.46 (0.28, 0.75)a<0.001
Non-DF/DF56/12457/12363/11762/118
Genistein11.01 (0.62, 1.64)0.78 (0.48, 1.26)0.78 (0.48, 1.26)0.204
Non-DF/DF39/14154/12667/11378/102
Daidzein10.60 (0.36, 1.01)0.44 (0.26, 0.74)a0.34 (0.21, 0.57)a<0.001
Non-DF/DF42/13853/12758/12284/96
Dihydrodaidzein10.73 (0.44, 1.21)0.65 (0.39, 1.08)0.34 (0.21, 0.56)a<0.001
Non-DF/DF46/13457/12360/12075/105
Equol10.85 (0.51, 1.3)0.71 (0.43, 1.17)0.48 (0.30, 0.78)a0.002
Non-DF/DF52/12865/11554/12667/113
O-Desmethylangolensin10.67 (0.42, 1.09)1.00 (0.61, 1.63)0.67 (0.41, 1.08)0.300

Odds ratios (ORs) and 95% CIs of dental fluorosis for quartiles of dietary intake and urinary levels of soy isoflavone.

OR, odds ratio; CI, confidence interval; DF, dental fluorosis; Q, quartile. The multivariate logistic regression model was used to estimate the association of dental fluorosis with dietary intake and urinary levels of soy isoflavone. Covariates were adjusted for age, gender, ethnicity, marital status, education level, smoking, alcohol drinking, tea drinking, improved stove use, fuel type and using coal to roast grains and chilies, washing dry grains and chilis before use, total energy intake, calcium intake.

a

p < 0.05.

Table 6

Soy isoflavonesQ1Q2Q3Q4p
Dietary intake (mg/day)
Non-SF/SF124/100137/87159/65154/70
Glycitein10.75 (0.49, 1.14)0.49 (0.31, 0.76)a0.61 (0.39, 0.95)a0.007
Non-SF/SF121/103143/81156/68154/70
Genistein10.65 (0.43, 0.99)a0.51 (0.33, 0.79)a0.60 (0.39, 0.93)a0.012
Non-SF/SF121/103144/80160/64149/75
Daidzein10.64 (0.42, 0.97)a0.47 (0.30, 0.74)a0.64 (0.42, 0.99)a0.020
Non-SF/SF121/103145/79156/68152/72
Total soy isoflavones10.61 (0.40, 0.94)a0.51 (0.33, 0.79)a0.60 (0.39, 0.93)a0.015
Urinary isoflavones (ng/mL)
Non-SF/SF112/68105/75123/57126/54
Glycitein11.13 (0.71, 1.80)0.67 (0.41, 1.08)a0.66 (0.41, 1.07)a0.023
Non-SF/SF112/68124/56111/69119/61
Genistein10.86 (0.53, 1.40)1.14 (0.72, 1.82)0.92 (0.57, 1.48)0.951
Non-SF/SF108/72105/75117/63136/44
Daidzein11.10 (0.69, 1.76)0.80 (0.49, 1.29)0.49 (0.30, 0.80)a0.002
Non-SF/SF97/83115/65119/61134/46
Dihydrodaidzein10.70 (0.44, 1.12)0.68 (0.43, 1.09)0.42 (0.26, 0.63)a0.001
Non-SF/SF107/73104/76123/57132/48
Equol11.11 (0.70, 1.77)0.68 (0.42, 1.09)0.56 (0.35, 0.91)a0.005
Non-SF/SF112/68120/60116/64118/62
O-Desmethylangolensn10.83 (0.52, 1.34)1.01 (0.63, 1.61)0.88 (0.55, 1.41)0.806

Odds ratios (ORs) and 95% CIs of skeletal fluorosis for quartiles of dietary intake and urinary levels of soy isoflavone.

OR, odds ratio; CI, confidence interval; SF, skeletal fluorosis; Q, quartile. The multivariate logistic regression model was used to estimate the association of skeletal fluorosis with dietary intake and urinary levels of soy isoflavone. Covariates were adjusted for age, gender, ethnicity, marital status, education level, smoking, alcohol drinking, tea drinking, improved stove use, fuel type and using coal to roast grains and chilies, washing dry grains and chilis before use, total energy intake, calcium intake.

a

p < 0.05.

4 Discussion

4.1 Summary of main findings

To the best of our knowledge, we firstly assessed the association of soy isoflavones with fluorosis. We observed that dietary intake of soy isoflavones, glycitein, daidzein and genistein were negatively associated with fluorosis. Additionally, the higher the urinary level of glycitein, daidzein, dihydrodaidzein and equol, were associated a lower occurrence of coal-burning fluorosis. Biomarkers are invaluable for providing objective, precise, and biologically relevant measures of nutrient status. Urinary isoflavone levels reflect metabolic processing and excretion, not merely dietary intake. Inter-individual metabolic differences must be considered, as they substantially influence urinary levels. However, the assessment of dietary soy isoflavones through FFQ can reflect the dietary levels of long-term habits, which is very important for exploring the relationship between dietary isoflavone and disease. In the present study, we investigated both dietary and urinary exposure of soy isoflavones, and we found both internal and external exposure levels of soy isoflavones was negatively associated the occurrence of fluorosis. These rigorous findings suggested that higher exposure level of soy isoflavones is associated with the lower the risk of coal-burning fluorosis. An experimental animal study on the effects of multi-nutrient intervention in coal-burning fluorosis on dental fluorosis, bone fluoride and urinary fluoride in female rats suggested that multi-element plus soy intervention resulted in lower bone fluoride levels (23). This may be attributed to the fact that soy foods are rich in soy isoflavones. A five-year cohort study (n = 1,587) found a 1.95% reduction in bone mineral density (BMD) and a 69% increased risk of osteoporosis (95% CI: 1.09, 2.61) in the lowest group compared to the highest quartile of soy isoflavones (≥62.64 mg/day) (24). In addition, studies have shown that increasing the intake of soy products, soy protein or soy isoflavones can improve bone resorption or reduce bone loss (14, 25). A recent meta-analysis of 26 randomized controlled trials (n = 2,652) also found that supplementation of soy isoflavones had a strong beneficial effect on estrogen deficient bone loss in women (26), and intervention of soy isoflavones can effectively improve lumbar spine and total femur bone mineral density in women (27, 28). Therefore, both observational and interventional studies have shown that soy isoflavones have beneficial effects on bone health. In this study, dietary and urinary soy isoflavones were found to be negatively correlated with fluorosis, which proves that the beneficial effects of soy isoflavones on bone health may antagonize the effects of fluorosis on bone injury. It is acknowledged that urinary isoflavone levels reflect metabolic processes and excretion rather than intake alone, and inter-individual metabolic variations affect these levels, which will be addressed in future studies.

4.2 Explanation of biological mechanisms

Excessive fluoride induces oxidative stress in bone tissues by increasing the content of reactive oxygen species (ROS) and lipid peroxides (MDA) in bone tissues and reducing the activity of antioxidant enzymes (20, 29). Although oxidative stress indicators were not directly measured, the antioxidant properties of isoflavones allow us to infer that they alleviate fluorosis by reducing oxidative stress damage. Soy isoflavones can affect fluorosis through their antioxidant properties because they are well-documented antioxidant substances. In recent years, studies have shown that soy isoflavones significantly elevated total antioxidant capacity and superoxide dismutase enzyme activities, decreased malondialdehyde level, promoting antioxidant element nuclear erythroid-2-related factor 2, and its downstream targets, including heme oxygenase 1, and quinone oxidoreductase 1 protein expressions (30). Furthermore, isoflavones can enhance bone formation and inhibit bone resorption by influencing the cell signaling pathways of osteoblast and osteoclast differentiation, including the Wnt-β-catenin and BMP pathways that stimulate bone formation (31). In addition, studies have shown that soy isoflavones are phytoestrogens with physiological functions such as preventing osteoporosis, increasing bone density and bone strength in rats with osteoporotic fractures, promoting the expression of vascular endothelial growth factor and osteoprotegerin at the fracture end, improving the histological environment, and promoting the healing of osteoporotic fractures (32, 33). Notably, although we detected dietary and urinary soy isoflavones and used multivariate analyses to demonstrate negative association, we did not measure urinary bone turnover markers, limiting direct evidence for bone health conclusions. Overall, the negative associations between soy isoflavones and fluorosis may be justified based on the fact that they act as antioxidants to reduce oxidative stress damage and have a positive effect on fluorosis. However, further studies are needed to elucidate the pathophysiological mechanism.

4.3 Gender-specific associations and the role of estrogen

In this study, stratified analysis showed soy isoflavones may be inversely associated with fluorosis in women, but not in men, indicating associations between soy isoflavones and fluorosis may be modified by gender. Some related studies have shown that the reduction of BMD loss by soy protein is mainly due to the phytoestrogenic effects of soy isoflavones (34, 35). A clinical study has shown that soy isoflavones can improve bone mineral density and prevent bone calcium loss in postmenopausal women, and soy isoflavones can also significantly slow down the bone turnover rate in postmenopausal women, which is beneficial to maintaining the dynamic balance of bone resorption-bone formation, and has the effect of preventing and treating osteoporosis in postmenopausal women (36). Sex-specific associations were also observed in other studies, such as colorectal cancer (37) and type 2 diabetes (38). The bases for the sex-specific effects may be soy isoflavones have at least two hydroxyl functions in opposite positions on the molecule, which mimics effect of estradiol. This may be attributed to the interaction between estrogen receptor expression levels in women and the phytoestrogenic effects of the isoflavones. Isoflavones not only act as weak estrogens but also compete with endogenous estrogen for binding to the estrogen receptor (39). ERα activates intracellular phosphorylation pathways including PI3K/Akt and NF-κB and exerting its biological effect (40). Additionally, menopausal status as a potentially important confounder in interpreting sex-specific findings. Postmenopausal women experience estrogen decline, whereas studies have demonstrated that soy isoflavone supplementation improves menopausal symptoms and postmenopausal bone health (41–43). Thus, postmenopausal estrogen decline can be partially offset by soy isoflavones acting as phytoestrogens. However, it was regrettable that we did not collect this status due to the estrogen levels of women gradually decrease after menopause. Future epidemiological studies need to determine whether estrogen biomarkers or menopausal status affect the effects of soy isoflavones on fluorosis risk.

4.4 Study limitations and directions for future research

Although this study has built upon existing literature, it is not without limitations. First, the cross-sectional design inherently restricts our ability to establish a causal relationship between isoflavones and fluorosis. However, we implemented stringent inclusion and exclusion criteria during participant recruitment to mitigate potential reverse causality to some extent. Second, while the Food Frequency Questionnaire (FFQ) may introduce measurement errors, the questionnaire utilized in this study has been validated, and we conducted a multifactorial analysis to minimize the influence of these errors on our findings. Third, although patients diagnosed with fluorosis may alter their dietary habits, such changes do not result in misclassification of their fluorosis status, allowing for some degree of generalizability of our results. Fourth, gender-stratified analysis was conducted, female menopausal status was not stratified due to we did not collect menopausal status during the investigation. Potential hormonal influences on the observed relationships was not explored. Future studies should collect data on menopausal status to clarify hormone-related effects. Additionally, we did not measure urinary bone turnover markers, limiting direct evidence for bone health conclusions. Finally, although we adjusted for major sociodemographic characteristics, lifestyle factors, dietary factors, confounding by unknown or unmeasured factors cannot be completely ruled out, such as hormonal level, bone turnover markers. Future research should focus on these issues. (1) Individual metabolic variations affect urinary soy isoflavone levels, how do metabolism-related gene polymorphisms affect the association between soy isoflavones and fluorosis? (2) How do menopausal status or hormone levels affect the association between soy isoflavones and fluorosis? (3) How do bone turnover markers affect the association between soy isoflavones and fluorosis? Therefore, In the future, large-scale prospective studies should be carried out to collect menopausal status, detect levels of hormone and bone turnover marker, and determine gene of the metabolic pathway and bone turnover, in order to clarify their roles in the relationship between soy isoflavones and fluorosis. Moreover, further studies are needed to elucidate the pathophysiological mechanism by animal intervention experiments.

5 Conclusion

The higher exposure level of soy isoflavones is associated with the lower the risk of coal-burning fluorosis. The study provides evidence-based support for developing dietary recommendations incorporating soy isoflavones to help reduce fluorosis risk in endemic areas. Thus, we advocate increasing dietary soy isoflavone intake, particularly in coal-burning fluorosis areas. Food manufacturers should develop high-isoflavone fortified foods for high-risk population. Multi-sectoral collaboration is needed to implement prevention strategies at the grassroots level, complemented by health education to enhance public self-protection awareness.

Statements

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Medical Ethics Committee of Zunyi Medical University (No. 2014-1-003). Written informed consent was obtained from all the participants. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

HH: Resources, Writing – review & editing. YL: Data curation, Writing – review & editing. PL: Data curation, Writing – review & editing. LL: Conceptualization, Writing – review & editing. XZhe: Conceptualization, Writing – review & editing. YZ: Formal analysis, Writing – original draft. ML: Investigation, Writing – review & editing. XZha: Methodology, Writing – review & editing. LT: Methodology, Writing – review & editing. MG: Investigation, Writing – review & editing. NT: Project administration, Writing – review & editing. JL: Funding acquisition, Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the National Natural Science Foundation of China (Grant No. 81460497), Joint Funding of Zunyi Medical University and Zunyi Science and Technology and Big Data Bureau for Scientific and Technological Research [ZSKHHZZ (2023) 167 and QKPTPR (2021) 1350-003].

Acknowledgments

The authors want to thank the study subjects for their participation and the students who are taking part in the recruitment of subjects and the interviews in the investigation. The authors also thank the CDC of Zhijin County for providing administrative support to our study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2025.1589177/full#supplementary-material

References

  • 1.

    ZengALiHHuXYangMMuMChenYet al. Fibroma development in rats with dental fluorosis: activation pathways of endoplasmic reticulum stress and mitochondria. J Zunyi Med Univ. (2021) 44:433–9. doi: 10.14169/j.cnki.zunyixuebao.2021.0071

  • 2.

    ZhouJSunDWeiW. Necessity to pay attention to the effects of low fluoride on human health: an overview of skeletal and non-skeletal damages in epidemiologic investigations and laboratory studies. Biol Trace Elem Res. (2023) 201:1627–38. doi: 10.1007/s12011-022-03302-7

  • 3.

    GuanZWuCQiX. Evaluation of the health status of the population in coal fired fluorosis areas in Guizhou Province after comprehensive management. J Guizhou Med Univ. (2018) 43:1124–8. doi: 10.19367/j.cnki.1000-2707.2018.10.001

  • 4.

    FanS. The current situation of endemic fluorosis prevention and control in China during the 13th five-year plan period. OEM. (2020) 37:1219–23. doi: 10.13213/j.cnki.jeom.2020.20274

  • 5.

    WangXGaoJLiCSongLZhangXPanX. Changes of fluorine exposure level of population in endemic fluorosis areas caused by coal burning in Guizhou Province. E&H. (2020) 37:620–2. doi: 10.16241/j.cnki.1001-5914.2020.07.012

  • 6.

    WangMShenHChenXLiYZhouXLaCet al. Meta-analysis on the effectiveness of health education interventions for endemic fluorosis in China. CJCED: Chin J Control Endem Dis. (2024) 39:16–9.

  • 7.

    JianyangGHongchenWZhiqiZJingfuWHaiqingL. Review on health impacts from domestic coal burning: emphasis on endemic fluorosis in Guizhou province, Southwest China. RECT. (2021):258. doi: 10.1007/398_2021_71

  • 8.

    HuoXWangSChenZet al. Effect of soy isoflavones on oxidative hydrogen peroxide-induced stress in IPEC-J2 cells. CJAVS: Guangdong J Anim Vet Sci. (2021) 46:37–40.

  • 9.

    YariZTabibiHNajafiIHedayatiMMovahedianM. Effects of soy isoflavones on serum systemic and vascular inflammation markers and oxidative stress in peritoneal dialysis patients: a randomized controlled trial. Phytother Res. (2020) 34:3011–8. doi: 10.1002/ptr.6729

  • 10.

    XiongXXuZHeNHeJChenZHuangCet al. Intervention of soy isoflavones in hepatic oxidative stress and inflammation in obese rats. Acta Agric Zhejiangensis. (2022) 34:942–8.

  • 11.

    GreendaleGATsengCHHanWHuangM-HLeungKCrawfordSet al. Dietary isoflavones and bone mineral density during midlife and the menopausal transition: cross-sectional and longitudinal results from the study of women’s health across the nation phytoestrogen study. Menopause. (2015) 22:279–88. doi: 10.1097/GME.0000000000000305

  • 12.

    BarańskaAKanadysWBogdanMStępieńEBarczyńskiBKłakAet al. The role of soy isoflavones in the prevention of bone loss in postmenopausal women: a systematic review with meta-analysis of randomized controlled trials. J Clin Med. (2022) 11:4676. doi: 10.3390/jcm11164676

  • 13.

    KanadysWBarańskaABłaszczukAPolz-DacewiczMDropBMalmMet al. Effects of soy isoflavones on biochemical markers of bone metabolism in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Int J Environ Res Public Health. (2021) 18:5346. doi: 10.3390/ijerph18105346

  • 14.

    AkhlaghiMGhasemi NasabMRiasatianMSadeghiF. Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci. (2020) 60:2327–41. doi: 10.1080/10408398.2019.1635078

  • 15.

    El-DemerdashAAtanasovABishayeeAAbdel-MogibMHooperJNAAl-MourabitA. Batzella, Crambe and Monanchora: highly prolific marine sponge genera yielding compounds with potential applications for cancer and other therapeutic areas. Nutrients. (2018) 10:33. doi: 10.3390/nu10010033

  • 16.

    Al-BariMAAHossainSMiaUAl MamunMA. Therapeutic and mechanistic approaches of Tridax procumbens flavonoids for the treatment of osteoporosis. Curr Drug Targets. (2020) 21:1687–702. doi: 10.2174/1389450121666200719012116

  • 17.

    QiaoLLiuXHeYZhangJHuangHBianWet al. Progress of signaling pathways, stress pathways and epigenetics in the pathogenesis of skeletal fluorosis. Int J Mol Sci. (2021) 22:1932. doi: 10.3390/ijms222111932

  • 18.

    ZhuJLiuJZhaoWZhangH. Protective effect of soy isoflavones on liver and kidney function injury in rats with fluorosis. CJCED: Chin J Control Endem Dis. (2016) 31:527.

  • 19.

    QinXWangSYuMZhangLLiXZuoZet al. Child skeletal fluorosis from indoor burning of coal in southwestern China. J Environ Public Health. (2009) 2009:969764. doi: 10.1155/2009/969764

  • 20.

    LiuJYangSLuoMJChenTMaXJTaoNet al. Association between dietary patterns and fluorosis in Guizhou, China. Front Nutr. (2019) 6:189. doi: 10.3389/fnut.2019.00189

  • 21.

    CuiQXiaYWuQChangQNiuKZhaoY. Validity of the food frequency questionnaire for adults in nutritional epidemiological studies: a systematic review and meta-analysis. Crit Rev Food Sci. (2023) 63:1670–88. doi: 10.1080/10408398.2021.1966737

  • 22.

    YangY. Chinese food ingredient list. Beijing: Peking University Press (2022).

  • 23.

    YuSWangFXiaS. Effects of multi-nutrient intervention on dental fluorosis, bone fluoride and urinary fluoride in female rats with coal burning fluorosis. E&H. (2017) 34:477–80.

  • 24.

    BagliaMLGuKZhangXZhengYPengPCaiHet al. Soy isoflavone intake and bone mineral density in breast cancer survivors. Cancer Cause Control. (2015) 26:571–80. doi: 10.1007/s10552-015-0534-3

  • 25.

    TangSDuYOhCNoJ. Effects of soy foods in postmenopausal women: a focus on osteosarcopenia and obesity. J Obes Metab Syndr. (2020) 29:180–7. doi: 10.7570/jomes20006

  • 26.

    MNTLHuLMJeppesenPB. A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women. Am J Clin Nutr. (2017) 106:801–11. doi: 10.3945/ajcn.116.151464

  • 27.

    Shams-WhiteMMChungMDuMFuZInsognaKLKarlsenMCet al. Dietary protein and bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation. Am J Clin Nutr. (2017) 105:1528–43. doi: 10.3945/ajcn.116.145110

  • 28.

    ZhengXLeeSKChunOK. Soy isoflavones and osteoporotic bone loss: a review with an emphasis on modulation of bone remodeling. J Med Food. (2016) 19:1–14. doi: 10.1089/jmf.2015.0045

  • 29.

    BabuSManoharanSOttappilakkilHPerumalE. Role of oxidative stress-mediated cell death and signaling pathways in experimental fluorosis. Chem Biol Interact. (2022) 365:110106. doi: 10.1016/j.cbi.2022.110106

  • 30.

    LuCWeiZJiangNChenYWangYLiSet al. Soy isoflavones protects against cognitive deficits induced by chronic sleep deprivation via alleviating oxidative stress and suppressing neuroinflammation. Phytother Res. (2022) 36:2072–80. doi: 10.1002/ptr.7354

  • 31.

    NakaiSFujitaMKameiY. Health promotion effects of soy isoflavones. J Nutr Sci Vitaminol. (2020) 66:502–7. doi: 10.3177/jnsv.66.502

  • 32.

    Gómez-ZoritaSGonzález-ArceoMFernández-QuintelaAEseberriITrepianaJPortilloMP. Scientific evidence supporting the beneficial effects of isoflavones on human health. Nutrients. (2020) 12:3853. doi: 10.3390/nu12123853

  • 33.

    AoRZhangJGuJYuTLiangWZhangT. The effect of soy isoflavones on osteoporotic fracture healing in ovariectomized rats. J Orthop. (2015) 18:110–3.

  • 34.

    SathyapalanTAyeMRigbyASFraserWDThatcherNJKilpatrickESet al. Soy reduces bone turnover markers in women during early menopause: a randomized controlled trial. J Bone Miner Res. (2017) 32:157–64. doi: 10.1002/jbmr.2927

  • 35.

    YellandSSteensonSCreedonAStannerS. The role of diet in managing menopausal symptoms: a narrative review. Nutr Bull. (2023) 48:43–65. doi: 10.1111/nbu.12607

  • 36.

    InpanRDukaewNNa TakuathungMTeekachunhateanSKoonrungsesomboonN. Effects of isoflavone interventions on bone turnover markers and factors regulating bone metabolism in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. (2024) 20:2. doi: 10.1007/s11657-024-01467-3

  • 37.

    KhankariNKYangJJSawadaNWenWYamajiTGaoJet al. Soy intake and colorectal cancer risk: results from a pooled analysis of prospective cohort studies conducted in China and Japan. J Nutr. (2020) 150:2442–50. doi: 10.1093/jn/nxaa194

  • 38.

    WooHWKimMKLeeYHShinDHShinMHChoiBY. Sex-specific associations of habitual intake of soy protein and isoflavones with risk of type 2 diabetes. Clin Nutr. (2021) 40:127–36. doi: 10.1016/j.clnu.2020.04.035

  • 39.

    WangYTianMHeHDuJ. Meta-analysis of safety of soy isoflavones in postmenopausal women. J Toxicol. (2018) 32:10. doi: 10.16421/j.cnki.1002-3127.2018.04.005

  • 40.

    Canivenc-LavierMCBennetau-PelisseroC. Phytoestrogens and health effects. Nutrients. (2023) 15:317. doi: 10.3390/nu15020317

  • 41.

    PokushalovEPonomarenkoAGarciaCKasimovaLPakIShrainerEet al. Assessing the combined effects of black cohosh, soy isoflavones, and SDG lignans on menopausal symptoms: a randomized, double-blind, placebo-controlled clinical trial. Eur J Nutr. (2025) 64:138. doi: 10.1007/s00394-025-03588-y

  • 42.

    ZhouYSuZLiuGHuSChangJ. The potential mechanism of soy isoflavones in treating osteoporosis: focusing on bone metabolism and oxidative stress. Phytother Res. (2025) 39:1645–58. doi: 10.1002/ptr.8451

  • 43.

    CuiYCaiHGaoYDaiQYangGZhengWet al. Associations of dietary intakes of calcium, magnesium and soy isoflavones with osteoporotic fracture risk in postmenopausal women: a prospective study. J Nutr Sci. (2022) 11:e62. doi: 10.1017/jns.2022.52

Summary

Keywords

soy isoflavones, dietary, coal-burning fluorosis, cross-sectional study, factor analysis

Citation

Han H, Li Y, Li P, Liu L, Zheng X, Zhang Y, Liu M, Zhang X, Tang L, Gao M, Tao N and Liu J (2025) A cross-sectional study of dietary and urinary soy isoflavones about coal-burning fluorosis in Guizhou, China. Front. Nutr. 12:1589177. doi: 10.3389/fnut.2025.1589177

Received

07 March 2025

Accepted

09 July 2025

Published

24 July 2025

Volume

12 - 2025

Edited by

Tong Wang, Duke University, United States

Reviewed by

Chen Chen, Shenzhen Maternity and Child Healthcare Hospital, China

Ye Cao, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Germany

Yuanyin Teng, Zhejiang University, China

Updates

Copyright

*Correspondence: Na Tao, ; Jun Liu,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics